Sugi Predict

Sugi Predict / Compounds / SCHEMBL307243

SCHEMBL307243

SCHEMBL307243

CC(C)(C)OC(=O)NC1CCc2nc(N)sc2C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN4A P35499 5/20 0.64
▸ SCN3A Q9NY46 5/20 0.56
▸ SCN9A Q15858 4/20 0.55
▸ DRD3 P35462 4/20 0.53
▸ DRD2 P14416 3/20 0.53
▸ HRH2 P25021 2/20 0.53
▸ ADRA2A P08913 2/20 0.53
▸ DRD4 P21917 2/20 0.53
▸ ADRB2 P07550 1/20 0.53
▸ HTR1A P08908 1/20 0.53
▸ ADRA2B P18089 1/20 0.53
▸ ADRA2C P18825 1/20 0.53
▸ HTR1B P28222 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ HTR7 P34969 1/20 0.53
▸ ADRA1A P35348 1/20 0.53
▸ HRH1 P35367 1/20 0.53
▸ HTR2B P41595 1/20 0.53
▸ SIGMAR1 Q99720 1/20 0.53
▸ HRH4 Q9H3N8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL307244 1.00 SCN4A (0.64) SCN4ASCN3ASCN9ADRD3DRD2
SCHEMBL2713962 1.00 SCN4A (0.64) SCN4ASCN3ASCN9ADRD3DRD2
SCHEMBL7939917 0.86 DRD3 (0.56) SCN4ASCN3ASCN9ADRD3DRD2
SCHEMBL29145448 0.86 SCN4A (0.49) SCN4ASCN3ASCN9ASCN5A
SCHEMBL28912415 0.86 SCN4A (0.49) SCN4ASCN3ASCN9ASCN5A
SCHEMBL15738520 0.86 SCN4A (0.49) SCN4ASCN3ASCN9ASCN5A
SCHEMBL28912414 0.86 SCN4A (0.49) SCN4ASCN3ASCN9ASCN5A
SCHEMBL14146257 0.85 SCN4A (0.48) SCN4ASCN3ASCN9ASCN5A
SCHEMBL21552301 0.84 NPC1 (0.49) SCN4A
SCHEMBL28912404 0.84 SCN4A (0.48) SCN4ASCN3ASCN9ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263547-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 — — EP disclosed
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-14 — — US disclosed
CN-112574191-B Isoxazole heterocyclic compound and application thereof 南京圣和药业股份有限公司 2024-01-23 — — CN disclosed
EP-4263547-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-10-25 — — EP disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20230117470-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS SYNGENE INTERNATIONAL LIMITED (IN) 2023-04-20 — — US disclosed
US-20230117470-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS SYNGENE INTERNATIONAL LIMITED (IN) 2023-04-20 — — US disclosed
EP-4051388-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS Bristol-Myers Squibb Company (US) 2022-09-07 — — EP disclosed
WO-2022128853-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-23 — — WO disclosed
EP-2630144-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2013-08-28 — — EP disclosed
US-20120270868-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-25 — — US disclosed
US-20120178752-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-12 — — US disclosed
WO-2012054367-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-26 — — WO disclosed
US-8093266-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-10 — — US disclosed
US-20100197679-A1 COMPOUNDS GLAXO GROUP LIMITED 2010-08-05 — — US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 — — US disclosed
EP-2114869-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-11-11 — — EP disclosed
WO-2008128961-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-10-30 — — WO disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 SCN4A 3807/4885SCN3A 3596/4885SCN9A 4484/4885
US-20120270868-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA SCN4A 4051/4885SCN3A 3302/4885SCN9A 3481/4885
US-20100197679-A1 COMPOUNDS NRDC, MRPL21, NISCH SCN4A 3401/4885SCN3A 3139/4885SCN9A 2168/4885
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA SCN4A 3282/4885SCN3A 3364/4885SCN9A 3293/4885
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 SCN4A 4298/4885SCN3A 3848/4885SCN9A 3028/4885
US-20120178752-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA SCN4A 4253/4885SCN3A 4007/4885SCN9A 3674/4885
US-20230117470-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS TLR1, TLR3, TLR9 SCN4A 2657/4885SCN3A 2184/4885SCN9A 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.